ClinicalTrials.gg
Not yet recruitingNCT07012525Updated Aug 22, 2025

Clinical Evaluation of Photobiomodulated Hyaluronic Acid Therapy for Interdental Papillary Loss: Minimal Invasive Blind Split Mouth Technique

A Phase 1/2 interventional study of Photobiomodulation Therapy + Hyaluronic Acid Gel Injection and Hyaluronic Acid Gel Injection in Interdental Papillae Reconstruction, sponsored by Dar Al Uloom University. Not yet recruiting at 1 site in Saudi Arabia. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Dar Al Uloom University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness of a minimally invasive therapy combining photobiomodulation (PBMT) with injectable dermal filler (hyaluronic acid) in adult patients (ages 20-40) with interdental papillary loss (Norland \& Tarnow Class I) in the maxillary anterior region.

The main questions it aims to answer are:

Does PBMT enhance the regenerative effect of hyaluronic acid filler in restoring the interdental papilla? Is the combined therapy superior to dermal filler alone in achieving long-term aesthetic and clinical stability?

Researchers will compare:

Group I (control) - hyaluronic acid filler alone vs. Group II (experimental) - PBMT applied before and after hyaluronic acid filler to see if PBMT contributes to better papilla height, width, and volume restoration over 12 months.

Participants will:

Undergo standard periodontal cleaning and education 4 weeks before treatment Receive local anesthesia and dermal filler injections in both quadrants (split-mouth design)

Have PBMT applied in one quadrant only (Group II) Be followed up at regular intervals (1 week to 12 months) for clinical measurements and digital image analysis of papilla dimensions This study introduces a non-surgical, patient-friendly technique that may enhance soft tissue regeneration in esthetic areas, offering a potential breakthrough in managing interdental papillary loss.

Read the detailed description

This study explores a novel, minimally invasive therapeutic approach to treating interdental papillary loss (IDP)-a condition with both functional and esthetic consequences, particularly in the maxillary anterior region. While surgical techniques for papilla regeneration have been investigated for decades, success has been limited due to anatomical challenges such as restricted blood supply and the small volume of tissue involved. Additionally, many of these procedures are invasive, complex, and do not guarantee long-term stability.

The proposed study evaluates the synergistic effect of photobiomodulation therapy (PBMT), formerly known as low-level laser therapy (LLLT), when combined with injectable hyaluronic acid (HA) dermal filler. PBMT is known to enhance microcirculation, stimulate fibroblast activity, and promote angiogenesis, all of which may contribute to improved tissue regeneration. HA, on the other hand, supports extracellular matrix remodeling, tissue hydration, and wound healing. While HA has shown some promise when used alone for papilla reconstruction, recurrence of papillary loss has been reported within 6-12 months post-treatment.

This clinical trial employs a split-mouth, randomized controlled design to compare two interventions within the same patient-HA filler alone versus HA combined with PBMT. By minimizing inter-patient variability, this design enhances internal validity and provides a more reliable comparison of treatment efficacy.

Throughout a 12-month follow-up period, the study will assess changes in papillary height, width, and overall tissue volume using standardized clinical measurements and digital imaging analysis. Additionally, the PBMT group will receive laser therapy at each follow-up session to evaluate its ongoing regenerative contribution.

This study aims to introduce a patient-friendly, conservative alternative to surgical procedures, with the potential to become a predictable and reproducible technique in the esthetic zone. If successful, it may offer a paradigm shift in managing one of the most challenging soft tissue defects in periodontal and esthetic dentistry.

02

Conditions studied

  • Interdental Papillae Reconstruction
03

In context

Lead sponsor

Dar Al Uloom University is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 to 40 years
  • Presence of at least two non-adjacent interdental papilla defects (Class I, Norland \& Tarnow classification) in the maxillary anterior region
  • Healthy periodontal status, with:
  • Probing depth ≤ 3 mm
  • No gingival recession
  • No tooth mobility (Score 0)
  • No interdental bone loss on radiographs
  • Non-smokers
  • No previous orthodontic treatment
  • Free from gingival or dental surface alterations (e.g., abfraction, irregularities, or overcontouring)
  • Systemically healthy (no systemic diseases or conditions affecting healing or immune function)
  • Willing and able to comply with study procedures and follow-up visits
  • Provided written after explanation of study procedures

Exclusion criteria

Exclusion Criteria:

  • Candidates will be excluded if they meet any of the following:
  • Systemic diseases or medications known to affect soft tissue healing (e.g., diabetes, )
  • Pregnancy or lactation
  • History of periodontal surgery in the study area
  • Known allergy or to hyaluronic acid or local anesthetics
  • Current use of anti-inflammatory drugs, anticoagulants, or antibiotics that could affect healing
  • Poor oral hygiene or non-compliance during pre-treatment phase
  • Participation in another clinical trial within the last 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Photobiomodulation + Hyaluronic Acid

    This arm includes the test sites (e.g., left maxillary quadrant) in each participant. The same dose of hyaluronic acid (0.2 mL of 0.8% gel) will be injected in the same manner as in the control group. However, photobiomodulation therapy (PBMT) using a diode laser (wavelength 630-670 nm, 25 mW, 1.875 J/cm² for 20 seconds) will be applied before and after the injection. Laser application will be repeated at every follow-up appointment to promote tissue healing, angiogenesis, and papillary regeneration.

    Procedure: Photobiomodulation Therapy + Hyaluronic Acid Gel Injection

  • Active comparator
    Hyaluronic Acid Gel Injection only

    This arm includes the control sites (e.g., right maxillary quadrant) in each participant. The interdental papilla with Class I deficiency will be treated using 0.2 mL of 0.8% commercial hyaluronic acid gel, injected 2-3 mm apical to the papilla tip. This is a commonly used non-surgical soft tissue filler in periodontal and esthetic procedures. No photobiomodulation therapy will be applied in this arm.

    Drug: Hyaluronic Acid Gel Injection

Interventions

  • ProcedurePhotobiomodulation Therapy + Hyaluronic Acid Gel Injection

    This arm includes the test sites (e.g., left maxillary quadrant) in each participant. The same dose of hyaluronic acid (0.2 mL of 0.8% gel) will be injected in the same manner as in the control group. However, photobiomodulation therapy (PBMT) using a diode laser (wavelength 630-670 nm, 25 mW, 1.875 J/cm² for 20 seconds) will be applied before and after the injection. Laser application will be repeated at every follow-up appointment to promote tissue healing, angiogenesis, and papillary regeneration.

  • DrugHyaluronic AcidStudies of Hyaluronic AcidHyaluronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This arm includes the control sites (e.g., right maxillary quadrant) in each participant. The interdental papilla with Class I deficiency will be treated using 0.2 mL of 0.8% commercial hyaluronic acid gel, injected 2-3 mm apical to the papilla tip. This is a commonly used non-surgical soft tissue filler in periodontal and esthetic procedures. No photobiomodulation therapy will be applied in this arm.

06

What researchers measure

Primary outcomes

  1. Change in Papillary Deficient Area

    This outcome measures the change in the total area of interdental papillary deficiency (in mm²), calculated using standardized measurements of papillary height and width. The area is estimated using the formula: Area = ½ × Papillary Width × Papillary Deficient Height. Method of Assessment: Clinical measurements with a UNC-15 probe and digital photographic analysis.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

Secondary outcomes

  1. Change in Papillary Width

    Measures the horizontal base width of the interdental papilla at the crestal level between adjacent teeth. Assessment Tool: Clinical probing and digital image analysis.

    Time frame: Baseline and follow-up at 1, 3, 6, and 12 months

  2. Change in Papillary Deficient Height

    Vertical distance (in mm) from the tip of the papilla to the contact point between adjacent teeth. Assessment Tool: Periodontal probe (UNC-15) and digital images.

    Time frame: Baseline and follow-up at 1, 3, 6, and 12 months

  3. Digital Image Analysis Score

    Quantitative assessment of papillary volume and soft tissue contour using standardized intraoral photographs and imaging software.

    Time frame: Baseline and follow-up at 1, 3, 6, and 12 months

  4. Patient Satisfaction and Aesthetic Score

    Patient-reported outcomes evaluating satisfaction with esthetics and comfort using a visual analog scale (VAS) from 0 to 10.

    Time frame: At 3, 6, and 12 months

  5. Incidence of Adverse Effects

    Monitors for soft tissue reactions, pain, inflammation, or infection at treatment sites.

    Time frame: throughout the study duration (from initial treatment up to 12 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Demographic data: age, sex, and quadrant assignment (test vs. control) Papillary measurements: Papillary width Papillary deficient height Calculated deficient area (mm²) Digital image analysis scores: baseline and all follow-up intervals Patient-reported outcomes: aesthetic satisfaction scores (VAS) Adverse events: type, frequency, and severity of any reported reactions All data will be anonymized to ensure participant confidentiality in accordance with applicable ethical and legal standards.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Start Date: Six months after publication of the primary study results in a peer-reviewed journal. End Date: Five years from the IPD availability start date.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 10, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012525
Lead sponsor
Dar Al Uloom University
Responsible party
Sally Abd-ElMeniem ElHaddad (Assist. Prof. Periodontology and Oral Medicine, Dar Al Uloom University) — Principal investigator
First posted
Jun 10, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 22, 2025

Study contacts

Sally A ElHaddad, Assist. Prof.
Contact
s.elhaddad@dau.edu.sa
+966555361062
SREIC Scientific Research Ethics and Innovative committee
Contact
cod.sreic@du.edu.sa
00966011494 ext. 9212
SREIC College of dentistry, Dar AlUloom University
study director · College of Dentistry, Dar AlUloom University, SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion